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Abstract 
Evidence from recent animal studies indicates that the analgesic effect of low frequency 
TENS is reduced in opioid tolerant animals.  The aim of the present study was to compare 
the analgesic effect of conventional (high frequency) and acupuncture-like (low 
frequency) TENS between a group of opioid treated patients and a group of opioid-naive 
patients in order to determine if this cross-tolerance effect is also present in humans.  
Twenty-three chronic pain patients (11 who took opioids and 12 who did not) participated 
in the study.  Participants were assigned in a randomized cross-over design to receive 
alternately conventional and acupuncture-like TENS.  There was a significant reduction 
in pain during and after conventional TENS when compared to baseline for both the 
opioid and non-opioid group (p<.01).  For acupuncture-like TENS however, the analgesic 
effect of TENS was only observed in the non-opioid group (p<.01), with opioid treated 
patients showing no change in pain scores during and after TENS when compared to 
baseline (p>.09).  The reduced analgesic effect of acupuncture-like TENS in opioid 
treated patients is coherent with previous animal studies and suggests that conventional 
TENS should be preferred in patients taking opioids on a regular basis. 
Perspective: This study shows that patients taking opioids on a regular basis are less 
susceptible to benefit from acupuncture-like TENS.  This phenomenon is probably 
attributable to the fact that the analgesia induced by acupuncture-like TENS and opioids 
are mediated by the same receptors (i.e. μ opioid receptors). 
Keywords: Transcutaneous electrical nerve stimulation (TENS), opioids, rehabilitation 
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Introduction 
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality 
commonly used in rehabilitation for pain relief.30  TENS applications are generally 
described according to the output characteristics of the device as either high frequency, 
low intensity (conventional TENS or CT) or low frequency, high intensity (acupuncture-
like TENS or AT).10, 14  The high frequency, low intensity stimulations employed by CT 
recruit Aβ fibers which, according to the gate control theory of pain, inhibit the 
transmission of nociceptive information in the dorsal horn of the spinal cord.14, 27, 40  
Alternately, the low frequency, high intensity stimulations used by AT activate Aδ and C 
fibers, producing counter-irritation analgesia via the recruitment of descending inhibition 
mechanisms.43 
There is growing evidence to suggest that the analgesic effect of TENS is 
associated with the release of endogenous opioids.8, 12, 20, 38  Interestingly, the type of 
opioid receptor subserving TENS analgesia would depend on the stimulation parameters 
used, with high frequency stimulations producing analgesia through δ opioid receptors 
and low frequency stimulations producing analgesia through μ opioid receptors.20, 23, 38  
The implication of opioid receptors in TENS analgesia could help to explain why the 
analgesic effect of TENS is sometimes found to decrease after repeated applications.13  
This tolerance phenomenon (which is well documented for opioids)36 was described by 
Chandran & Sluka7 who also noticed that animals rendered tolerant to high and low 
frequency TENS were tolerant to δ and μ opioid agonists, respectively.  Moreover, the 
same group have shown that animals that were made tolerant to morphine (a μ opioid 
receptor agonist) were also tolerant to low frequency TENS.39  In contrast, the analgesic 
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effect of high frequency TENS (which is believed to act on δ opioid receptors) was 
preserved in morphine-tolerant rats, suggesting that this cross-tolerance phenomenon is 
receptor specific. 
If the same results are found in human, the studies of Sluka and colleagues7, 39 can 
have several important implications for the clinician.  First, and because the vast majority 
of opioids target μ opioid receptors,17 they would suggest that AT tolerant patients would 
retain less benefits from opioid analgesics than patients who are not tolerant to AT.  
Second, they would propose that the analgesic effect of AT would be considerably 
decreased in opioid-tolerant patients.  In 1980, Solomon et al.41 reported that the 
analgesic effect of TENS for post-operative pain was reduced in patients who had used 
narcotics prior to surgery compared to patients who had not used narcotics before 
surgery.  These results  suggests that the “cross-tolerance” phenomenon observed 
between TENS and opioids in rodents is also present in humans.39  Nevertheless, two 
important limitations prevent us from making any clear assertions. First, the results of 
Solomon et al. were based on posteriori analyses and should therefore be considered 
exploratory until confirmed by other studies.  Second, and most importantly, the 
stimulation parameters for TENS were not specified by Solomon et al., making it 
impossible to determine if the “cross-tolerance” effect observed by the authors were 
between opioid analgesics and AT or between opioid analgesics and CT.  Thus, the 
purpose of this study was to compare the analgesic efficacy of CT and AT between a 
group of patients who took opioids on a regular basis and a group of patient who did not 
use opioids for more than 6 months.  Based on the work of Sluka et al.,39 we 
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hypothesized that the analgesic efficacy of AT (but not CT) would be decreased in 
patients who took opioids on a regular basis. 
Materials and Methods 
Participants 
Twenty-three chronic pain patients (11 who took opioids on a daily basis for more 
than 4 months and 12 who did not use opioids for more than 6 months) participated in the 
study.  Four patients from the non-opioid group previously took opioids for their pain 
condition but the medication was stopped more than 6 months before testing (mean time 
since medication was stopped ± SD = 25.8 ± 23.9 months).  Participants were recruited 
through ads posted in local newspapers, physiotherapy clinics and in the Sherbrooke 
University Hospital’s Pain Clinic.  All participants had localized pain of diverse origin 
(e.g. spinal disc herniation, osteoarthritis, chondromalacia) for more than 6 months.  For 
security reasons, patients with demand-type cardiac pacemakers and pregnant women 
were excluded.  Every participant was asked to refrain from using short term analgesics 
two hours before testing and from taking caffeine and smoking cigarettes six hours before 
testing.  Participants’ characteristics are presented in Tables 1 and 2. 
The experiment took place at the Clinical Research Centre of the Sherbrooke 
University Hospital, in Sherbrooke, Quebec, Canada.  The Research Ethics Board for 
Human Subjects of the Sherbrooke University Hospital approved the study’s procedures 
and each participant provided informed consent before participation.   
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Experimental design and TENS stimulation protocol 
Participants were assigned in a randomized cross-over design to receive, 
alternately, CT and AT.  The order of presentation of the two types of TENS stimulations 
was determined using a random number table.  This resulted in 11 participants receiving 
CT before AT, and 12 participants receiving AT before CT.  Every participant was 
submitted to the two types of stimulation (approx. 1 week interval).  At each visit, a 
thorough examination was made by the experimenter to determine the precise location of 
the pain.  The painful area’s margins were marked carefully with a pen in order to ensure 
optimal electrode placement.  Participants were placed in a comfortable position, 
generally lying on their stomach (ventral decubitus) on a mobilization table.  Pillows 
were given to ensure proper positioning. 
TENS stimulations were delivered using a pair of rubber silicone electrodes 
connected to a digital Eclipse Plus apparatus (Empi, St-Paul, Minnesota).  The electrodes 
were placed over the painful area identified previously.  Electrodes’ position was 
reassessed with the TENS stimulator turned ON in order to be certain that induced 
paresthesias entirely covered the painful region.  In cases where stimulations did not 
properly cover the painful region, the stimulator was turned OFF and the electrodes were 
repositioned.  For CT, the frequency was set at 100 Hz, the pulse duration at 60 s, and 
the intensity was adjusted to produce strong and comfortable (innocuous) tingling 
sensations.  For the AT, the frequency was set at 3 Hz, the pulse duration at 250 s and 
the intensity was adjusted to produce strong and painful sensations (pain tolerance 
threshold).  For both CT and AT, the stimulation was applied for 25 minutes and the 
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intensity was occasionally raised (based on the participant’s sensation) to account for 
nerve accommodation and to maintain the same level of sensation.34, 42 
Pain intensity and unpleasantness was evaluated using two separate numerical 
rating scales (NRS) (intensity 0 = no pain, 100 = most intense pain imaginable; 
unpleasantness 0 = not unpleasant, 100 = most unpleasant pain imaginable).  Pain 
intensity (sensory-discriminative component) and unpleasantness (motivational-affective 
component) are two distinct components of pain which are associated with distinct 
anatomical regions of the pain matrix.2  The distinctions between pain intensity and pain 
unpleasantness was explained successfully to the participants by using the analogy of 
Price and colleagues.32  Participants were asked to evaluate the intensity and 
unpleasantness of their clinical pain at three occasions: (1) before TENS application, (2) 
during TENS application (i.e. after 15 minutes of stimulation) and (3) immediately after 
TENS application.  The Patient Global Impression of Change (PGIC) scale  was also used 
after each TENS application to document participants’ overall evaluation of their 
treatment.11, 18 
 
Data analysis 
Because of the relatively small number of subjects included in this study, and 
since visual inspection of the histograms and normality tests (Shapiro-Wilk) did not allow 
us to assume that the data were normally distributed, non-parametric tests were used.  
Differences were considered to be significant if p < 0.05 was obtained.  All tests were 
performed using SPSS (version 13.0 for Windows®, Chicago, IL, USA). 
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Results 
Pain intensity and unpleasantness scores obtained prior to CT and AT applications 
showed that every participant experienced pain before TENS application (all baseline 
NRS scores  10).  Furthermore, Mann-Whitney tests conducted to test for group 
differences in baseline NRS scores revealed no significant group effect (all p-values > 
.19), indicating that the opioid and non-opioid group had comparable pain intensity and 
unpleasantness scores before TENS application. 
TENS stimulation threshold and intensities are shown in Table 3.  As it can be 
seen from the table, stimulation threshold and intensities for AT were similar between the 
opioid and non-opioid groups (p  .40).  For CT, however, stimulation threshold and 
stimulation intensities were consistently higher in the opioid group (p ≤ .03). 
 
Pain intensity 
Mean pain intensity scores obtained for each group before, during, and after CT 
and AT applications are shown in Figure 1A and 1B, respectively.  There was a 
significant decrease in pain intensity during and after CT for both the opioid and non-
opioid group.  For AT however, only the non-opioid group showed a reduction in pain 
intensity.  These differential effects were confirmed by the non-parametric analyses.  
First, Friedman’s Test for CT revealed that there was a significant change in pain 
intensity across the different time measures for both the opioid and non-opioid groups (all 
p-values <.001).  Post-hoc Wilcoxon Signed-Rank Tests showed that there was a 
significant reduction in pain intensity during and after CT in both the opioid and non-
opioid groups when compared to baseline (all p-values <.01).  For the AT, Friedman’s 
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Test revealed a significant change in pain intensity across the different time measures 
only for the non-opioid group (p<.001), while there was no change for the opioid group 
(p=.09).  Post-hoc tests for the non-opioid group showed that there was a significant 
reduction in pain intensity during and after AT when compared with baseline (all p-
values <.01). 
Between-group analyses using Mann-Whitney Tests revealed significant 
differences between the opioid and non-opioid groups for pain intensity during (p<.01) 
and after (p<.05) AT but not before AT (p>.18), suggesting that the variable “group” only 
had and effect on pain intensity during and after AT stimulations.  There was no 
difference between the opioid and non-opioid groups for pain intensity before (p=.24), 
during (p=.74), and after (p=.29) CT. 
 
Pain unpleasantness 
Analyses performed for pain unpleasantness revealed the same pattern of results.  
That is, Friedman’ Tests for CT showed a significant change in pain unpleasantness 
across the different times measures for both the opioid and non-opioid groups (all p-
values <.001).  Post-hoc Wilcoxon Tests showed that there was a significant reduction in 
pain unpleasantness during and after CT in both the opioid (all p-values <.05) and non 
opioid group (all p-values <.01) when compared with baseline (see Figure 2A).  For AT, 
Friedman’s Tests revealed a significant change in pain unpleasantness across the different 
time measures only for the non-opioid group (p<.001), while there was no change for the 
opioid group (p=.36).  Post-hoc Wilcoxon Tests for the non-opioid group showed that 
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there was a significant reduction in pain unpleasantness during and after AT when 
compared with baseline (all p-values <.01; see Figure 2B). 
Between-group analyses using Mann-Whitney Tests revealed significant 
differences between the opioid and non-opioid groups for pain unpleasantness during 
(p<.01) and after (p<.05) AT but not before AT (p>.18), suggesting again that the 
variable “group” only had and effect on pain unpleasantness during and after AT 
stimulations.  There was no difference between the opioid and non-opioid group for pain 
unpleasantness before (p=.46), during (p=.38), and after (p=.13) CT. 
 
Percentages of pain reductions 
In order to directly compare the analgesic effect of TENS stimulations, 
percentages of pain reductions obtained during CT and AT were calculated for each 
group [pain reduction = (pain before TENS - pain during TENS)/pain before TENS * 
100].  These percentages are illustrated in Figure 3.  As it can be seen from the figure, the 
analgesic effect of AT was substantially reduced in opioid patients.  The reduced 
analgesic effect of AT in the opioid group was confirmed by the Wilcoxon Signed-Rank 
Test and by the Mann-Whitney Test which showed (i) that there was a significant 
difference in analgesia between CT and AT for the opioid group (p<.01) and (ii) that 
there was a significant difference in AT analgesia between the opioid and non-opioid 
groups (p<.01).  Comparisons between CT and AT analgesia for the non-opioid group 
and comparisons of CT analgesia between the opioid and non-opioid groups revealed no 
significant differences (all p-values >.10). 
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PGIC scores 
PGIC scores for the CT and AT are represented in Table 4.  As it can be seen 
from the table, the majority of patients from both the opioid and non-opioid groups 
reported significant improvements following CT stimulations.  For AT however, less than 
half of the participants from the opioid group reported improvements following TENS, 
while the vast majority of the non-opioid group continued to benefit from the TENS.  
These between-group differences for the AT stimulations were confirmed by the Fisher’s 
exact test which showed that there was a greater proportion of patients who benefited 
from the stimulations (very much improved, much improved or minimally improved) in 
the non-opioid group than in the opioid group (p<.05).  There was no difference between 
the two groups for the CT stimulations (p=.48). 
Influence of participants’ characteristics on TENS analgesia 
In order to verify if participants’ characteristics influenced TENS analgesia, we 
performed exploratory analyses to determine if there was an association between AT and 
CT analgesia (measured during TENS stimulation) and the variables “Age”, “Sex”, 
“Time since onset of symptoms”, “Pain rating index”, “Physical functioning”, 
“Depression scores” and “Pain catastrophizing”.  For both the opioid and non-opioid 
group, Spearman tests showed that none of these variables were correlated with AT or CT 
analgesia (all p-values > .07).  For the opioid group, we also verified if there was an 
association between TENS (CT and AT) analgesia and the duration of opioid treatment.  
Again, the Spearman test revealed no significant correlation (all p-values > .48). 
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Linear regression model 
Because analyses of the participants’ characteristics revealed that both groups 
were not fully comparable (see Table 2), we performed linear regression analyses to 
determine if the variable “Group” could still explain AT analgesia after adjusting for 
“Age”, “Sex”, “Time since onset of symptoms”, “Pain rating index”, “Physical 
functioning”, “Depression scores” and “Pain catastrophizing”.  Because the dependant 
variable was not normally distributed, distributions of the residuals were inspected and 
analysed to confirm the validity of the regression model.  Results showed that the 
variable “Group” was still significant to explain AT analgesia (β=.65, p<.05) after the 
inclusion of the other variables in the regression analysis model.  Except for the variable 
“Group”, no variable was a significant predictor of AT analgesia (all p-values > 0.3).  
Visual inspection and analyses of the standardized and unstandardized residuals using the 
Shapiro-Wilk test revealed that the residuals were normally distributed (p=.97). 
 
Discussion 
 The current results suggest that the analgesic effect of AT is reduced in patients 
taking opioids on a regular basis.  Conversely, the analgesic effect of CT appears to be 
preserved in these patients.  Such observations are coherent with the work of Sluka et 
al.39 who showed that low frequency (but not high frequency) TENS was less effective in 
reducing secondary heat hyperalgesia in morphine-tolerant rats.  They also confirm and 
extend the results of Solomon et al.41 who documented that the analgesic effect of TENS 
for post-operative pain was reduced in patients who had used narcotics prior to surgery 
compared to patients who had not used narcotics before surgery. 
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 The reduced analgesic effect of AT in opioid-treated patients was observed both 
for pain intensity and pain unpleasantness.  Similarly, and for the other conditions where 
TENS was found to be effective (i.e. AT in participants from the non-opioid group and 
CT in participants from both groups), pain intensity and unpleasantness behaved 
similarly, with patients showing a reduction both in pain intensity and unpleasantness 
during and after TENS.  Although closely linked, pain intensity (sensory-discriminative) 
and unpleasantness (motivational-affective) are two separate components of pain which 
are associated with distinct anatomical regions of the pain matrix.2  Our results indicate 
(i) that TENS application can reduce both the sensory-discriminative and motivational-
affective component of pain and (ii) that opioid consumption blocks the effect of AT on 
these two components concurrently. 
Recent evidence from animal models suggests that TENS act on different opioid 
receptors, depending on the frequency employed.  Specifically, low frequency TENS has 
been shown to activate μ opioid receptors whereas high frequency TENS has been shown 
to activate δ opioid receptors.20, 38  These results are supported by human studies that 
showed that small doses of naloxone (blocking for the most part μ opioid receptors)17 are 
able to reverse AT but not CT analgesia.1, 8, 15, 19, 24, 37, 44  Alternately, large doses of 
naloxone (which are believed to ensure adequate blockage of all opioid receptor 
subtypes)3, 5 were shown to reverse CT analgesia.23  The interaction between AT and 
opioids (but not between CT and opioids) observed in the present study indirectly 
confirm these observations.  In particular, the reduced analgesic effect of AT in opioid-
treated patients could be seen as a confirmation that AT and opioids are mediated through 
the same receptors (i.e. μ opioid receptors).  Since cross-tolerance does not occur between 
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μ and δ opioid receptors,21 the preserved analgesic effect of CT in these patients would 
further suggest that CT analgesia is mediated by non-μ opioid receptors (i.e. δ or κ opioid 
receptors). 
From a clinical perspective, our results suggest that a patient taking opioids on a 
regular basis would be less susceptible to benefit from AT stimulations.  This does not 
exclude that some of these patients could benefit from AT stimulations.  In fact, five out 
of 11 participants from the opioid group reported some improvements on the PGIC scale 
after AT stimulations, indicating that the analgesic effect of AT is not completely and 
systematically hindered in all patients taking opioids.  However, and given the general 
pattern observed, clinicians would certainly be advised to initially try CT in this group of 
patients.  This appears particularly important when we consider that previous exposition 
to ineffective treatments can significantly reduce the analgesic effect of subsequent 
treatments.9 
Recently, Ram et al.33 showed that the analgesic effect of a standard counter-
irritation paradigm (i.e. immersion of right hand in painfully cold water) was reduced in 
opioid- treated patients.  The results from the present study support and extend the results 
of Ram et al. by showing that the analgesic efficacy of AT (another counter-irritation 
technique) is also reduced in opioid-treated patients.  Taken together, these observations 
would suggest that the analgesic effect of counter-irritation techniques, in general, is 
reduced in opioid- treated patients. 
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Influence of participants’ characteristics on TENS analgesia 
Our results showed that there was no association in both the opioid and non-
opioid group between participants’ characteristics and the analgesic effect of TENS.  
However, it is important to remember that the objective of the present study was not to 
evaluate the influence of these factors on TENS analgesia.  Additional research looking at 
the effect of variables such as depression scores and pain catastrophizing level on the 
analgesic effect of TENS is warranted. 
 
Stimulation thresholds and intensities 
 Our analyses revealed that there were no group differences for AT stimulation 
threshold and stimulation intensities.  For CT however, stimulation threshold and 
intensities were consistently higher in the opioid group when compared to the non-opioid 
group.  Traditionally, administration of opioids have been shown to induce hypoalgesia 
and thermal hypoaesthesia without alteration of fine touch and proprioception.4, 16, 26  
Somewhat challenging this view are the observations of Park et al.31 who showed that the 
non-noxious perceptual thresholds to high frequency electrical stimulations (250 and 
2000 Hz) were decreased following alfentanil administration.  On the contrary, there was 
no change in non-noxious perceptual thresholds when thresholds were measured with low 
frequency electrical stimulations (5 Hz) and conventional Von Frey hairs. 
Physiologically, μ opioid receptors are present in small-sized and medium-sized 
sensory neurons.45  The elevation of warm and noxious detection thresholds following 
opioid administration is coherent with the function of these fibers which are known to 
transmit information relative to pain and temperature.25  The changes in non-noxious 
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electrical thresholds are somewhat more puzzling when we consider that large-sized 
fibers do not typically express opioid receptors.35  The recent observations of Sasaki et 
al.35  could help to shed some light on these contradictory findings.  In their study, Sasaki 
et al. showed that μ opioid receptors – which were present almost exclusively in small-
sized and medium-sized sensory neurons in a group of naive mice – were largely 
expressed in large sensory neurons in mice suffering from herpetic pain. 
Taken together, the results of Sasaki et al. and our results suggest that opioids can 
alter non-noxious electrical stimulation thresholds and that these alterations are 
particularly susceptible to occur in people suffering from certain pain conditions.  It 
nevertheless remains unclear why we observed higher stimulation thresholds and 
intensities for non-noxious (high frequency) but not for noxious (low frequency) 
stimulations.  As suggested by Park et al.31, it is probable that the effect of opioids on the 
perception of electrical stimulation is highly dependant upon the frequency of the 
electrical stimulation.  Clearly, future studies are necessary to examine this question. 
 
Limitations 
An important limitation of the present study concerns the group differences 
observed in participants’ characteristics.  For example, we observed higher Beck 
Depression Inventory scores in the opioid group compared to the non-opioid group, 
suggesting that participants from the opioid group had more symptoms of depression and 
more emotional distress.  Although non-significant, a number of other measures also 
tended to be more elevated in the opioid group (e.g. McGill Pain Questionnaire scores).  
This raises some important questions.  For instance, one could wonder if the reduced 
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analgesic effect of AT in participants from the opioid group could not be explain by the 
fact that these patients had more symptoms of depression rather than because they took 
opioids on a regular basis.  Without completely excluding this possibility, the preserved 
analgesic effect of CT in the opioid group tends to discredit this interpretation.  
Obviously, and if the group differences were to be responsible for the difference in TENS 
analgesia, these differences would tend to be observed not only for AT but also for CT. 
Nevertheless, and since CT and AT are believed to exert their analgesic effect via 
distinct neurophysiological mechanisms (i.e. segmental inhibition vs descending 
inhibition), the preserved analgesic effect of CT cannot entirely rule out the possibility 
that the results for AT were not influenced by participants’ characteristics.  The group 
differences for the indices of depression appear particularly problematic when we 
consider that serotonin neurotransmission (which was shown to be altered in major 
depressive dirsorders)6, 28 plays a crucial role in descending pain modulation.29  In an
attempt to dissipate these doubts, we performed a linear regression analysis to determine 
if the variable “Group” could still explain AT analgesia after adjusting for participants’ 
characteristics.  Results showed that the variable “Group” was still a significant predictor 
of AT analgesia despite the inclusion of the other variables in the regression analysis 
model, suggesting that the group differences in participants’ characteristics are not 
responsible for the group difference in AT analgesia. 
An additional limitation concerns the absence of placebo.  By comparing the 
placebo condition to the active treatment condition, it would have been possible to 
determine if the analgesic effect of an intervention was superior to its placebo effect.  
Because the aim of the present study was to determine if the overall analgesic effect of 
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TENS differed between opioid treated patients and opioid-naive patients (and not to 
determine if the analgesic effect of TENS was superior to placebo TENS), we did not 
include a placebo TENS condition. 
Finally, it should be noted that the present study did not allow us to determine if 
the patients in the opioid group actually developed opioid tolerance.  Thus, and despite 
the fact that these participants took opioids on a regular basis for more than 4 months, it 
is impossible to ascertain if the reduced analgesic effect of TA in this group of 
participants is attributable to a “cross-tolerance” effect.  Questioning this cross-tolerance 
hypothesis is the work from Le Bars et al.22 who showed that a single intravenous 
injection of morphine could block counter-irritation analgesia in healthy participants, 
indicating that the antagonistic effect of opioids on counter-irritation analgesia is present 
well before the development of opioid tolerance.  Conversely, the reduced analgesic of 
AT reported by Sluka et al.39 was observed on Sprague-Dawley rats who received 
morphine pellets for 10 days (a procedure which was shown by Sluka et al. to induce 
morphine tolerance).  Whether the reduced analgesic of AT in our patients taking opioids 
is dependent on the induction of opioid tolerance remains unknown. 
 
Conclusion 
In the present study, we showed that the analgesic effect of CT was comparable 
between the opioid and non-opioid groups, suggesting preserved CT analgesia in opioid- 
treated patients.  For AT however, the analgesic effect of TENS was only observed in the 
non-opioid group, with opioid-treated patients showing no change in pain scores during 
and after TENS stimulation.  Taken together, these results propose that AT is less 
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effective than CT in opioid-treated patients and that CT stimulations should be preferred 
in patients taking opioids on a regular basis.  
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Figure Legends 
Figure 1.  Pain intensity before, during and after TENS for (A) CT and (B) AT.  Both 
groups (opioid and non-opioid) showed a reduction in pain intensity during and after CT 
(all p-values <.01) when compared to baseline.  For AT, there was a significant reduction 
in pain intensity during and after TENS for the non-opioid group (all p-values <.01) but 
not for the opioid group (p=.09).  Between-group comparisons revealed that there were 
significant differences between the opioid and non-opioid group during (p<.01) and after 
(p<.05) AT.  
A 
B 
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Figure 2.  Pain unpleasantness before, during and after TENS for (A) CT and (B) AT.  
There was a significant reduction in pain unpleasantness during and after CT both in the 
opioid (p<.05) and non-opioid group (p<.01) when compared to baseline.  For AT, there 
was a significant reduction in pain unpleasantness during and after TENS for the non-
opioid group (p<.01) but not for the opioid group (p=.36).  Between-group comparisons 
revealed that there were significant differences between the opioid and non-opioid group 
during (p<.01) and after (p<.05) AT. 
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Figure 3.  TENS analgesia during CT and AT stimulations (** p<.01). 
